Piper Jaffray initiates coverage on Rigel Pharmaceuticals (Nasdaq: RIGL) with an Overweight rating. Price target $13.

Piper analyst says, "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE